BCAX: Bicara Therapeutics Inc Kompaniya qiymatining sof foydaga nisbati

Bicara Therapeutics Inc - BCAX emitenti grafik logotipi

Bicara Therapeutics Inc. tibbiy sinovlarni o'tkazish uchun investitsiya kapitaliga tayanadi. Foyda ko'rsatkichi aktivning joriy tebranishlarini aks ettiradi, bunda -2.90 qiymati ushbu darajani belgilaydi. O'sish antitanachalar ishlab chiqish uchun sog'liqni saqlash gigantlari bilan hamkorlik qilish orqali ta'minlanmoqda. Shu bilan birga, ushbu ishlanmalarning gumanitar maqsadlari global siyosiy risklarning biznesga ta'sirini minimallashtiradi.

Narx-foyda koeffitsiyenti: Bicara Therapeutics Inc. (BCAX) 05.06.2025 - 15.11.2026 uchun

Bicara Therapeutics Inc (BCAX) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- aksiya kursi va ekspertlarning narx prognozi:
- bozor kapitallashuvi haqida ma'lumot:
Kompaniyaning jamlanma tahlili:Bicara Therapeutics
Bicara Therapeutics yetakchi tovari

Barqaror aktivlarning professional tanlovi haddan tashqari qimmat baholangan qimmatli qog'ozlarni chiqarib tashlash uchun bozor kapitalizatsiyasini haqiqiy foyda generatsiyasi bilan solishtirishga asoslanadi. Kompaniyaning yillik P/E ko'rsatkichini tahlil qilish orqali investor aksiya narxining sof foydaga nisbatini ko'radi, bu esa Bicara Therapeutics Inc. (BCAX) holatida dori vositalarini yetkazib berish paytida ixtisoslashtirilgan tibbiy logistika va sovuq zanjir talablariga rioya qilish uchun yuqori xarajatlarni qoplashning biznes imkoniyatlarini aks ettiradi.

Muhim raqobatchilar

ONC: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti HALO (Halozyme Inc.)|RVMD (RevMed) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori AAPG (ascentage.com)|CGON - Narx-foyda koeffitsiyenti|URGN: Narx-foyda koeffitsiyenti|PSNL - P/E multiplikatori|Erasca Corp (ERAS) - Narxning foydaga nisbati|Delcath - Kompaniya qiymatining sof foydaga nisbati|YMAB (Y-mAbs Therapeutics Inc) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Aura Biosciences, Inc. AURA|P/E multiplikatori CADL|P/E multiplikatori Accuray (ARAY)|Narxning foydaga nisbati SELLAS Life Sciences Group Inc. SLS|ACTU - Narx-foyda koeffitsiyenti|CTOR: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati HURA (TuHURA Biosciences Inc.)|TARA (Protara Therapeutics) - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning foydaga nisbati Fate Therapeutics Corp (FATE)|Narx-foyda koeffitsiyenti WHWK|Narx-foyda multiplikatori TCRX (TScan Therapeutics, Inc.)|P/E multiplikatori CSBR|XBIT - Kapitalizatsiyaning foydaga nisbati|CEL-SCI Corporation - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati OSTX|radiopharmtheranostics.com - P/E multiplikatori|ARTV: Narxning foydaga nisbati|ANL (adlainortye.com) - Narx-foyda koeffitsiyenti|VERU - Biznesning o‘zini qoplash muddati|TPST (Tempest Therapeutics, Inc.) - P/E multiplikatori|P/E multiplikatori xiliotx.com|Narxning foydaga nisbati Enochian BioSciences (RENB)|Narxning foydaga nisbati MURA (Mural Oncology PLC)|Narxning foydaga nisbati Kairos Pharma Ltd KAPA|P/E multiplikatori OnKure Therapeutics Inc OKUR|CytoMed Therapeutics - P/E multiplikatori|Biznesning o‘zini qoplash muddati Curis CRIS|APLM: P/E multiplikatori|Narx-foyda koeffitsiyenti Tharimmune, Inc.|ADVB (Advanced Biomed) - P/E multiplikatori|Genprex - Kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga nisbati calidibio.com (CLDI)|SBFM (Sunshine Biopharma Inc.) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori XBIO (Xenetic Biosciences)|Salarius Pharmaceuticals (SLRX) - Kapitalizatsiyaning foydaga nisbati|PPBT: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati AONC (American Oncology Network, Inc.)|BeOne Medicines (BGNE) - Narxning foydaga nisbati|Checkpoint Therapeutics, Inc (CKPT) - P/E multiplikatori|Narxning foydaga nisbati Elevation Oncology, Inc.|ICAD: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati ikenaoncology.com (IKNA)|Narxning foydaga nisbati NTBL (Notable Labs, Ltd.)|P/E multiplikatori VIRX (viracta.com)|MOR - Narx-foyda koeffitsiyenti|NAYA - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati AAPGV